Abstract
Objective
To investigate the status of diagnosis and treatment of primary breast cancer in Beijing, 2008.
Methods
All the patients who were diagnosed as primary breast cancer in Beijing in 2008 were enrolled in this study. Information of these patients, including the features of tumors, clinical diagnosis and treatment was collected, and filled in the well-designed questionnaire forms by trained surveyors. The missing data were partly complemented through telephone interviews.
Results
A total of 3473 Beijing citizens were diagnosed as primary breast cancer (25 patients with synchronal bilateral breast cancer) in Beijing, 2008. Of them 82.09% were symptomatic. 19.02% and 34.11% were diagnosed using fine needle aspiration biopsy (FNAB) and core needle biopsy (CNB), respectively. 15.92% received sentinel lymph node biopsy (SLNB) and 24.27% received breast conserving surgery (BCS). Among 476 cases with Her-2 positive, only 96 received anti-Her-2 therapy. We found that the standardization level varied in hospitals of different grades, with higher level in Grade-III hospitals. Of note, some breast cancer patients received non-standard primary tumor therapy: 65.63% of the patients with ductal carcinoma in situ (DCIS) received axillary lymph node dissection and 36.88% received chemotherapy; 25.89% of the patients underwent breast conserving surgery without margin status; 12.10% of the patients received chemotherapy less than 4 cycles.
Conclusion
Although most breast cancer patients received basic medical care, the mode of diagnosis and treatment should be improved and should be standardized in the future in Beijing.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr.
National Comprehensive Cancer Network (NCCN). Breast Cancer. 2008. V2.2. Available from: http://www.nccn.org/profes sionals/physician_gls/PDF/breast.pdf. Accessed on June 10, 2008.
Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18:1133–1144.
Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63:181–187.
Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007; 9:R6.
Cronin KA, Harlan LC, Dodd KW, et al. Population-based Estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US [J]. Cancer Investigation 2010; 28:963–968.
Chen SL, Hoehne FM, Giuliano AE. The Prognostic Significance of Micrometastases in breast cancer: a SEER population-based analysis. Ann Surg Oncol 2007; 14:3378–3384.
Hill DA, Nibbe A, Royce ME, et al. Method of detection and breast cancer survival disparities in Hispanic women [J]. Cancer Epidemiol Biomarkers Prev 2010; 19:2453–2460.
Rosen PP, Groshen S, Kinne DW, et al. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 1993; 11:2090–2100.
Rosen PP, Groshen S, Kinne DW. Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study. J Clin Oncol 1991; 9:1650–1661.
Fisher ER, Anderson S, Redmond C, et al. Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants[J]. Cancer 1993; 71:2507–2514.
Truong PT, Berthelet E, Lee J, et al. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer 2005; 103:2006–2014.
Smith JA 3rd, Gamez-Araujo JJ, Gallager HS, et al. Carcinoma of the breast: analysis of total lymph node involvement versus level of metastasis. Cancer 1977; 39:527–532.
Lee AK, DeLellis RA, Silverman ML, et al. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol 1990; 8:1457–1465.
Bettelheim R, Penman HG, Thornton-Jones H, et al. Prognostic significance of peritumoral vascular invasion in breast cancer. Br J Cancer 1984; 50:771–777.
Veronesi U, Galimberti V, Mariani L, et al. Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. Eur J Cancer 2005; 41:231–237.
Naik AM, Fey J, Gemignani M, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg 2004; 240:462–471.
Rescigno J, Zampell JC, Axelrod D. Patterns of axillary surgical care for breast cancer in the era of sentinel lymph node biopsy. Ann Surg Oncol 2009; 16:687–696.
Alderman AK, Bynum J, Sutherland J, et al. Surgical treatment of breast cancer among the elderly in the United States. Cancer 2010; [Epub ahead of print].
Japanese Breast Cancer Society. Results of questionnaires concerning breast cancer surgery in Japan 1980–2003. Breast Cancer. 2005; 12:1–2.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by the grant from Beijing Municipal Science & Technology Commission (No. D09050703650902).
Contributed equally to this study.
Rights and permissions
About this article
Cite this article
Yuan, Xm., Wang, N., Ouyang, T. et al. Current status of diagnosis and treatment of primary breast cancer in Beijing, 2008. Chin. J. Cancer Res. 23, 38–42 (2011). https://doi.org/10.1007/s11670-011-0038-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11670-011-0038-y